Comparative Pharmacology
Head-to-head clinical analysis: CALCIBIND versus SEVELAMER CARBONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CALCIBIND versus SEVELAMER CARBONATE.
CALCIBIND vs SEVELAMER CARBONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CALCIBIND (sodium polystyrene sulfonate) is a cation-exchange resin that exchanges sodium ions for potassium ions in the gastrointestinal tract, primarily in the colon, thereby reducing serum potassium levels.
Sevelamer carbonate is a phosphate-binding polymer that binds dietary phosphate in the gastrointestinal tract, thereby reducing phosphate absorption and serum phosphate levels. It also binds bile acids and may reduce LDL cholesterol.
5 mg orally once daily, taken without food or with a low-fat meal.
Adults: 800 to 1600 mg orally three times daily with meals, titrated according to serum phosphorus targets.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours in patients with normal renal function; prolonged to 12-24 hours in severe renal impairment (eGFR <30 mL/min), necessitating dose adjustment.
Not applicable. Sevelamer carbonate is not systemically absorbed and thus has no measurable plasma half-life. Its pharmacological effect correlates with gastrointestinal transit time, which is typically 24-48 hours.
Primarily renal (90% as unchanged drug via glomerular filtration and tubular secretion). Biliary/fecal: 10% (unabsorbed drug and metabolites).
Sevelamer carbonate is not absorbed systemically; it acts locally in the gastrointestinal tract. Excretion is entirely fecal, with no renal or biliary elimination. The polymer is excreted unchanged in the feces.
Category C
Category A/B
Phosphate Binder
Phosphate Binder